Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBUS: Pomalidomide + Low-Dose Dex vs High-Dose Dex in RRMM
NCT01311687Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2011
- Primary completion
- Mar 2013
- Modality
- Molecular Glues
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free Survival at 57 weeks. Started Mar 2011; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01311687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01311687.